磷酸西格列汀对2型糖尿病患者血脂的影响

摘要
图/表
参考文献(16)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的观察磷酸西格列汀对2型糖尿病患者血脂的影响。方法选取2013年7月～2014年11月我院收治的40例2型糖尿病患者，均给予磷酸西格列汀（100 mg，1次/d）治疗24周，观察治疗前后患者的空腹血糖、餐后2 h血糖、糖化血红蛋白、体重指数、血脂、血尿酸的变化。结果治疗12周后与治疗前相比，患者的空腹及餐后血糖、糖化血红蛋白均有所降低（P＜0.05），但体重指数、总胆固醇、三酰甘油、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血尿酸均无明显变化（P＞0.05）；治疗24周后与治疗前相比，患者的空腹及餐后血糖、糖化血红蛋白、总胆固醇、三酰甘油及低密度脂蛋白胆固醇均显著降低（P＜0.05），但体重指数、高密度脂蛋白胆固醇及血尿酸无显著性变化（P＞0.05）。结论磷酸西格列汀可有效控制2型糖尿病患者的血糖水平，同时改善血脂水平。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	路盈
	邹水兰
	孔霞

关键词 ：磷酸西格列汀, 2型糖尿病, 血糖, 血脂

Abstract：Objective To observe the impact of sitagliptin phosphate on blood lipid of patients with type 2 diabetic. Methods 40 patients with type 2 diabetic admitted into our hospital from July 2013 to November 2014 were selected. All patients were treated with sitagliptin phosphate（100 mg,once a day）for 24 weeks.The changes of fasting blood glucose,2 hours postprandial hyperglycemia,glycosylated hemoglobin,body weight index,blood lipid and blood uric acid in patients were observed before and after treatment. Results Compared with treatment for 12 weeks and before treatment, the level of fasting blood glucose,postprandial hyperglycemia,glycosylated hemoglobin was decreased（P＜0.05）,body weight index,total cholesterol,triglyceride,high density lipoprotein cholesterol,low density lipoprotein cholesterol and blood uric acid had no obvious change（P＞0.05）.Compared with treatment for 24 weeks and before treatment,the level of fasting blood glucose,postprandial hyperglycemia,glycosylated hemoglobin,total cholesterol,triglyceride and low density lipoprotein cholesterol was obvious decreased（P＜0.05）,but body weight index,high density lipoprotein cholesterol and blood uric acid had no obvious change（P＞0.05）. Conclusion Sitagliptin phosphate can effective control blood glucose of patients with type 2 diabetic and improve blood lipid level.

Key words： Sitagliptin phosphate Type 2 diabetes Blood glucose Blood lipid

作者简介: 路盈（1982-），女，硕士，主治医师，研究方向：内分泌与代谢疾病的诊治

引用本文:

路盈;邹水兰;孔霞. 磷酸西格列汀对2型糖尿病患者血脂的影响[J]. 中国当代医药, 2016, 23(2): 121-123.
LU Ying;ZOU Shui-lan;KONG Xia. Impact of sitagliptin phosphate on blood lipid of patients with type 2 diabetes. 中国当代医药, 2016, 23(2): 121-123.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2016/V23/I2/121

[1]	中华医学会糖尿病学分会.中国2型糖尿病防治指南（2013年版）[J].中华糖尿病杂志，2014，6（7）：447-448.
[2]	de Valk HW.DPP-4 inhibitors and combined treatment in type 2 diabetes:re-evaluation of clinical success and safety[J].Rev Diabet Stud，2007，4（3）：126-133.
[3]	Chia CW，Egan JM.Incretin-based therapies in type 2 diabetes mellitus[J].Clin Endocrinol Metab，2008，93（10）：3703-3716.
[4]	Drucker DJ.Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes:preclinical biology and mechanisms of action[J].Diabetes Care，2007，30（6）：1335-1343.
[5]	Tian L，Gao J，Hao J，Zhang Y，et al.Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidaseⅣinhibitor[J].Endocrinology，2010，151 （7）：3049-3060.
[6]	Herman-Hermen W，Johnson J，Teng R，et al.Efficacy and safety of initial combination therapy with sitagliptin andmetformin in patients with type 2 diabetes：a 54-week study[J].Curr Med Res Opin，2009，25（3）：569-583.
[7]	Herman DW，Johnson J，TengR，et al.Efficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetes[J].Diabetes Obes Metab，2010，12（5）：442-451.
[8]	Vilsll T，Rosenstock J，Yki-J rvinen H，et al.Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes [J].Diabetes Obes Metab，2010，12（2）：167-177.
[9]	Migoya EM，Stevens CH，Bergman AJ，et al. Effect of moderate hepatic insufficiency on the pharmacokinetics of pharmacokinetics of sitagliptin[J].Can J Clin Pharmacol，2009，16（1）：165-170.
[10]	Raz I，Chen Y，Wu M，et al.Efficacy and safety of Sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes [J]. Curr Med Res Opin，2008，24（2）：537-550. [11] Nonaka K，Kakikawa T，Sato A，et al.Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes [J].Diabetes Res Clin Pract，2008，79（2）：291-298.
[12]	Hermansen K，Kipnes M，Luo E，et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor,sitagliptin,in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin[J].Diabetes Obes Metab，2007，9（5）：733-745.
[13]	Aschner P，Katzeff HL，Guo H，et al.Efficacy and safety of monotherapy of sitagliptin compared with metformin inpatients with type 2 diabetes[J]. Diabetes Obes Metab，2010，12（1）：1-10.
[14]	Iwamoto Y，Tajima N，Kadowaki T，et al.Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes：a randomized，double blind trial[J].Diabetes Obes Metab，2010，12（7）：613-622.
[15]	Boschman M，Engeli S，Dobberstein K，et al.Dipeptidyl peptidaseⅣinhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients[J].J Clin Endocrinol Metab，2009，94（3）：846-852.
[16]	Karasik A，Charbonnel B，Liu J，et al.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone [J]. Diabetes Care，2006，29（12）：2638-2643.